-
Innovation Ranking
Innovation Ranking – VBI Vaccines Inc
VBI Vaccines Inc (VBI), a subsidiary of FDS Pharma LLP is a biopharmaceutical company that discovers and develops novel vaccines in the therapeutic areas of immuno-oncology and infectious diseases. The company’s pipeline vaccine candidates include cytomegalovirus, PreHevbrio, glioblastoma multiforme and zika virus. It utilizes technologies such as eVLP platform, and thermostable platform to develop the vaccine candidates. VBI offers Sci-B-Vac, a hepatitis B vaccine which consists of surface antigens of hepatitis B virus and is free of any next-generation adjuvant....
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VBI-1501 in Cytomegalovirus (HHV-5) Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VBI-1501 in Cytomegalovirus (HHV-5) Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VBI-1501 in Cytomegalovirus (HHV-5) Infections Drug Details: VBI-1501A (CMV Vaccine) is...
-
Product Insights
NewNet Present Value Model: Ionis Pharmaceuticals Inc’s Donidalorsen Sodium
Empower your strategies with our Net Present Value Model: Ionis Pharmaceuticals Inc's Donidalorsen Sodium report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Company Insights
Innovation and Patenting activity of VBI Vaccines Inc Q1 2024
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of VBI Vaccines Inc Q1 2024". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VBI-1901 in Recurrent Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VBI-1901 in Recurrent Glioblastoma Multiforme (GBM) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VBI-1901 in Recurrent Glioblastoma Multiforme (GBM) Drug Details: VBI-1901...
-
Product Insights
NewMeasles – Drugs In Development, 2024
Empower your strategies with our Measles – Drugs In Development, 2024 report and make more profitable business decisions. Measles is a highly infectious viral disease. The virus lives in the mucus of the nose and throat of people with this infection. Physical contact, coughing, and sneezing can spread the infection. Symptoms of measles are high temperature, sore eyes (conjunctivitis), and a runny nose, which usually occur first; small white spots usually develop inside the mouth a day or so later, with...
-
Product Insights
NewSevere Acute Respiratory Syndrome (SARS) – Drugs In Development, 2024
Empower your strategies with our Severe Acute Respiratory Syndrome (SARS) – Drugs In Development, 2024 report and make more profitable business decisions. Severe acute respiratory syndrome (SARS) is a serious, potentially life-threatening viral infection caused by virus from the Coronaviridae family. Symptoms include cough, chills and shaking, headache, muscle aches, diarrhea, dizziness, nausea, and vomiting. Risk factors include gene variation in the immune system and close contact with someone who has SARS. The Severe Acute Respiratory Syndrome (SARS) drugs in development...
-
Product Insights
NewMedulloblastoma – Drugs In Development, 2024
Empower your strategies with our Medulloblastoma – Drugs In Development, 2024 report and make more profitable business decisions. Medulloblastoma is the most common malignant brain tumor in children. Medulloblastoma by definition occurs in the cerebellum, which is the part of brain located at the base of the skull, just above the brainstem. Symptoms associated with a medulloblastoma include headaches in the morning that improve as the day goes on, recurrent vomiting, and difficulty with walking and balance. Medulloblastoma can spread to...
-
Product Insights
NewMiddle East Respiratory Syndrome (MERS) – Drugs In Development, 2024
Empower your strategies with our Middle East Respiratory Syndrome (MERS) – Drugs In Development, 2024 report and make more profitable business decisions. Middle East respiratory syndrome (MERS) is a viral respiratory disease caused by a coronavirus (MERS-CoV). Symptoms include fever, cough, and shortness of breath. Other symptoms include nausea, vomiting, and diarrhea. Pneumonia is common, and organs damage can occur to the kidneys or other organs. Treatment is aimed at relieving symptoms (joint pain and fever) with fluids and medications. The...
-
Product Insights
NewZika Virus Infections – Drugs In Development, 2024
Empower your strategies with our Zika Virus Infections – Drugs In Development, 2024 report and make more profitable business decisions. Zika virus infection is caused by a virus transmitted primarily by Aedes mosquitoes. Zika virus is a member of the Flaviviridae family. Symptoms include fever, skin rashes, conjunctivitis, muscle and joint pain, malaise, and headache. Risk factors include being in tropical and subtropical areas. Zika virus can also be transmitted through sexual intercourse. Treatment is aimed at relieving symptoms (joint pain...